Oncology

Cancer cells
#ASCO #Cancer therapeutics #Cancer treatment #Cancer vaccine #Oncology

Five 2024 breakthroughs in cancer drug research

With the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from 30 May to 3 June, the drug discovery announcements have been coming thick and fast, with many new cancer therapies making significant strides forward in our ability to treat the disease. Lorbrena advances… Read More

#Cancer Research #News #Trending News

Ozempic Insulin injection pen
#ASCO #Case Western Reserve University #Oncology #Weight loss

Ozempic reduces risk of 13 types of cancer

Patients taking semaglutide (the active ingredient in Wegovy and Ozempic) were 19% less likely to develop 13 obesity-related cancers, according to new data presented at ASCO 2024. The research, led by the Case Western Reserve University in Ohio and reported in The Guardian, also found… Read More

#Cancer Research #News #Trending News

Cancer research in lab
#Antigen #Immunology #Oncology #Prostate cancer #University of California San Francisco

Study reveals insights into antigen reactivity in prostate cancer

Researchers from the University of California, San Francisco (UCSF) shared new data on foundational prostate cancer antigen research at the 2024 Annual Meeting of the American Association of Immunologists (AAI) in Chicago. Prostate cancer’s low mutation burden has resulted in very few druggable neoantigens –… Read More

#Cancer Research #News

Conference speaker
#ASCO #Clinical trials #Drug discovery #Events #Oncology #Preclinical investigations

ASCO 2024 research highlights

As well as key findings with regards to lorlatinib for lung cancer, epcoritamab in follicular lymphoma, and pembrolizumab for bowel cancer, there were other significant study results revealed at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. RP1 and RP2 for melanoma… Read More

#Cancer Research #News #Trending News

#Microbiome #Neurodegenerative disorders #Oncology #Plant-based #Sepsis #Weight loss

New DDW Highlights podcast: 4 June 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The selected news highlights this week report breakthrough findings from early phase research and… Read More

#News

Bispecific antibodies
#AbbVie #ASCO #Bispecific Antibodies #Follicular lymphoma #Genmab #Haematology #Oncology

95% response to bispecific antibody in follicular lymphoma

Previously untreated follicular lymphoma (FL) patients who received epcoritamab with rituximab-lenalidomide (R2) had a 95% overall response rate (ORR), according to preliminary trial data. The results of two ongoing Phase I/II clinical trials evaluating cancer immunotherapy epcoritamab, a T-cell engaging bispecific antibody, were shared at… Read More

#Cancer Research #News #Trending News

Vaccine
#BioNTech #Cancer vaccine #Clinical trials #mRNA #Oncology #UK

NHS England launches country-wide cancer vaccine trials

Thousands of cancer patients in England are set to gain fast-tracked access to trials of mRNA personalised cancer vaccines following the launch of an NHS trial ‘matchmaking’ service to help find new life-saving treatments. The vaccines being jointly developed by biopharmaceutical companies BioNTech and Genentech are… Read More

#Cancer Research #News #Trending News

#Microbiome #Neurodegenerative disorders #Oncology #Plant-based #Sepsis #Weight loss

This week in drug discovery (27-31 May) 

News round-up for 27-31 May by DDW Senior Digital Content Editor Diana Spencer. The selected news highlights this week report breakthrough findings from early phase research and development, mainly preclinical studies and Phase I clinical trials, including a drug that can prevent sepsis deaths, a microbiome based immuno-oncology… Read More

#News

The microbiome
#Biomica #Gut microbiome #Microbiome #Oncology #Phase I trial

Microbiome therapeutic shows potential in refractory cancers

Biomica has revealed encouraging initial findings from an ongoing Phase I clinical trial of its microbiome-based immuno-oncology candidate, BMC128, in combination with an anti-PD1 immune checkpoint inhibitor. The trial is assessing the drug in patients with non-small cell lung cancer (NSCLC), melanoma, or renal cell… Read More

#Cancer Research #Editor's Choice #News

#Bone disease #Collaboration #Heart disease #mRNA #Oncology #Partnership

This week in drug discovery (20-24 May) 

News round-up for 20-24 May by DDW Senior Digital Content Editor Diana Spencer. The headline news this week emphasises the importance of shared expertise and collaboration, whether that be between nations, companies or research institutions, to enable the greatest advances in drug discovery. The top stories:… Read More

#News

Herpes virus cells
#Brain cancer #CureSearch #Herpes virus #LifeArc #MD Anderson Cancer Center #Oncology #Paediatrics

Could a modified cold sore virus cure brain cancer?

A team of scientists in the US and the UK are combining a genetically modified cold sore virus with a cancer vaccine to treat an aggressive type of brain cancer in children. The three-year survival rate for children with high-grade gliomas, without further complications, is only… Read More

#Cancer Research #Editor's Choice #News

#Immunotherapy #Interview #Oncology #RNA

The role of RNA in immunotherapies

Reece Armstrong speaks to Samuel Deutsch, Chief Scientific Officer of Nutcracker Therapeutics about the RNA landscape and how it can benefit the development of immunotherapies. RA: What role does RNA play in the development of effective immunotherapies? SD: The ability of RNA therapies to use the body’s own mechanisms to… Read More

#Cancer Research #Exclusive Content

#Artificial intelligence (AI) #Cancer research #Clinical trial design #Oncology

From data to cure: The journey of AI in cancer trials

Deepika Khedekar, Associate Centralized Clinical Trial Lead at IQVIA Inc, looks at the challenges of utilising artificial intelligence (AI) in oncology clinical research. Ten million1 people around the world die from cancer each year. Yet, while the number of cancer clinical trials has soared from 19,211… Read More

#Cancer Research #Exclusive Content